The H19 gene is the core upon which BioCancell’s technology is based. Prof. Avraham Hochberg, founder and Chief Scientist of BioCancell, is the pioneer and leader in H19 research. H19 is found abundantly in the human placenta and in several embryonic tissues, but is silenced after birth and re-appears in cancer cells.

H19 is a long, non-coding RNA, which does not code for a protein product. H19 plays a key role in the development, progress, drug resistance and metastasis of most human cancers. More and more studies are highlighting the central role of H19 in all stages of cancer.

BioCancell uses the cancer-specific mechanism of H19’s regulatory elements as an operating switch to activate its highly selective anti-cancer therapy.